Oxford University Press's
Academic Insights for the Thinking World

  • Author: Karyn Hede

First biosimilar drug approved for sale in the United States

New options for biologic cancer treatment are coming for the first time to the United States, and their arrival could help drive down costs for some of the biggest-ticket items in cancer care. Treatments that interfere with cancer’s biological underpinnings have revolutionized treatment for some cancers. But their cost now accounts for half of oncology drug spending—up from 11% a decade ago, according to the IMS Institute for Healthcare Informatics.

Read More